Verastem, a biopharmaceutical company listed on NASDAQ under the ticker symbol VSTM, has received a significant boost in its investment outlook. Analysts at BTIG Research have upgraded Verastem to a “strong-buy” rating, as detailed in a note issued to investors on March 5, 2024. This upgrade highlights growing confidence in the company’s potential in the oncology sector.
Several other research firms have also expressed positive sentiments regarding Verastem. Jefferies Financial Group reaffirmed a “buy” rating and set a price target of $19.00 for the stock. Meanwhile, HC Wainwright initiated coverage with a “buy” rating and a target price of $18.00. In contrast, Weiss Ratings maintained a “sell (d-)” rating on the shares earlier in January. According to MarketBeat.com, the stock currently holds an average rating of “buy” with a price target of $16.83, reflecting a consensus among analysts regarding its growth potential.
Quarterly Earnings and Stock Performance
Verastem reported its quarterly earnings on March 4, 2024, revealing a loss of ($0.50) earnings per share (EPS), slightly below analysts’ expectations of ($0.49). The company generated revenue of $17.54 million, surpassing the anticipated $16.85 million. Analysts project that Verastem will post an EPS of ($3.02) for the current year, indicating ongoing challenges as it navigates the competitive biopharmaceutical landscape.
Despite the positive ratings from analysts, Verastem’s stock experienced a decline of 4.1% following the earnings announcement. This fluctuation highlights the volatility often associated with biopharmaceutical companies, particularly those in clinical stages.
Insider Activity and Institutional Investments
In recent insider transactions, CEO Dan Paterson sold 10,321 shares of Verastem on January 12, 2024, at an average price of $7.16, totaling approximately $73,898. After this sale, Paterson retained ownership of 400,104 shares valued at about $2.86 million. CFO Daniel Calkins also sold 5,039 shares during the same period, resulting in a total transaction value of $36,079. These sales reflect a strategic adjustment, as both executives reduced their holdings by 2.51% and 4.59%, respectively.
Over the past ninety days, insiders have sold a total of 17,678 shares, indicating a shift in ownership dynamics. Currently, insiders hold 2.10% of the company’s stock.
Institutional investment has also played a significant role in Verastem’s market activity. Several hedge funds have increased their stakes, notably Polar Capital Holdings Plc, which boosted its holdings by 270.7% in the fourth quarter, now owning 3,925,126 shares valued at $30.3 million. Other notable investors include Armistice Capital LLC and Farallon Capital Management LLC, who have also purchased substantial stakes in the company.
Verastem, headquartered in Needham, Massachusetts, focuses on developing small molecule therapies aimed at treating various forms of cancer. Its leading product, COPIKTRA (duvelisib), is an oral inhibitor targeting specific pathways related to cancer stemness and resistance.
As the company continues to evolve and respond to market conditions, observers will monitor its next steps closely, especially in light of recent analyst upgrades and insider transactions.
